Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$11.26
$0.04(0.36%)
At close: 4:00 PM EDT
$11.26
$0.04(0.36%)
Day’s Range― - ―
52-Week Range$3.97 - $15.40
Previous CloseN/A
Volume1.35M
Average Volume (3M)4.09M
Market Cap
$1.56B
Enterprise Value$307.29
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 05, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume4,389,808
30 Day Avg. Volume4,091,092
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.14Price Target Upside114.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.14M
Bulls Say, Bears Say
Bulls Say
Robust Late‑stage Clinical DatasetTwo pivotal Phase III trials with >1,000 patients and unprecedented 26‑week blinded follow‑up create a durable evidence base for efficacy and safety. A robust, long‑duration dataset strengthens regulatory arguments, label differentiation and payer discussions over the medium term.
Rolling NDA Submission And Priority VoucherA rolling NDA pathway plus a Commissioner’s National Priority Voucher materially shortens potential approval timelines once filing is complete. Structurally, expedited review capability improves first‑mover prospects and reduces regulatory timing uncertainty relative to peers.
Commercial Readiness And Funded RunwayRecent financing that provides runway into 2028, combined with active commercial hires and scaling, gives the company durable capacity to build sales infrastructure and execute a launch. Sustained funding reduces immediate execution risk while commercialization ramps.
Bears Say
Pre‑revenue With Persistent Cash BurnThe company is pre‑revenue and has sustained large operating losses and negative free cash flow across periods. Reliance on external financing is structural until revenue begins, constraining flexibility, diluting stakeholders over time, and raising execution risk for commercialization plans.
Balance‑sheet Volatility And Prior Negative EquityA prior episode of negative equity followed by material swings signals reliance on financing events and valuation volatility. Persistent weak returns on equity and an unstable capital structure can limit strategic options, increase cost of capital and deter long‑term partners.
Reimbursement, REMS And Payer Sequencing RisksCategory III CPT status, pending RUC valuation, REMS details and DEA/rescheduling sequencing create structural access and reimbursement risk. Even with approval, these unresolved elements can meaningfully delay coverage, limit payment levels and slow provider uptake over multiple quarters.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $3.97 and its highest was $15.40 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $1.56B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of -$0.439 by $1.149.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.39.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $0.71 in its last earnings report, beating expectations of -$0.439. Following the earnings report the stock price went up 16.969%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.14 (114.41% Upside)
$24.14 (114.41% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$24.14
▲(114.41% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.41% Insiders
1.29% Mutual Funds
1.17% Other Institutional Investors
91.90% Public Companies and Individual Investors